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Brunsting-Perry pemphigoid (BPP) constitutes a rare variant of mucous membrane 
pemphigoid (MMP). Since the first description of 7 cases, there have been only few 
case reports describing the characteristics of BPP.1,2  
We have retrospectively assessed all BPP patients evaluated in our tertiary referral 
center between 2016 and 2019. The data was retrieved from our databank. 
Diagnosis of BPP was based on 1) clinical features 2) histopathological findings and 
3) positive direct immunofluorescence microscopy studies with linear deposits of IgG, 
IgA and/or C3 along the dermo-epidermal junction.3  
We identified 12 patients complying with the inclusion criteria. Patients’ 
characteristics and findings are depicted in Table I. The mean age at presentation 
was 73 years, 80% of the patients were male; 36.4% had diabetes mellitus type II, 
72.7% arterial hypertension, 54.5% chronic renal insufficiency and one suffered from 
colon cancer. There were three DPP4i-treated patients (25%), 4 patients (33.3%) 
received sartans. Ten of 11 patients (data missing for one patient) were treated with 
topical steroids. Among them, 8 had a relapse and required an additional treatment 
with methotrexate and/or tetracyclines. Complete remission, partial remission on 
minimal therapy and persistent disease were observed in 33.3%, 50%, and 16.7%, 
respectively.  
 
This review of 12 cases represents the largest series of BPP reported so far in the 
English literature. Without any exceptions the lesions involved the head, face or neck, 
and in >40% also the upper body. More than 90% of our patients presented with 
erosions, ulcerations and prurigo-like lesions, while obvious blistering was absent in 
almost half the patients. (Fig.1) In one third of the cases, mild oral mucosal 
involvement occurred, which has been only anecdotally reported in BPP.1,2 The 
polymorphic presentation likely explains the long mean diagnostic delay of 3 years 
observed in our series.  
Immunologically, the majority of our BPP patients showed reactivity for BP180 and/or 
BP230, although the available data indicates that the targeted autoantigens of BPP 
are heterogenous, including type VII collagen and laminin-332.2 
There is no validated therapeutic approach for BPP. Based on our observations, 
potent topical steroids should be the first-line therapeutic option. If the latter does not 










good second-line options.3 These regimens resulted in either complete or partial 
control of the disease on minimal treatment in more than 80% of our cases. In our 
study, 7 BPP patients were either on DPP4is or sartans. Drug-induced MMP has 
been only anecdotally described.2,4 DPP4is, as well as anti-PD1 inhibitors, have been 
associated with MMP and BP.4 Hence, our findings suggest that DPP4is may be a 
potential trigger of BPP. Furthermore, sartans have been incriminated in triggering 
both BP and MMP.4,5 
In summary, dermatologists should consider BPP in the presence of chronic localized 
erosions, ulcerations, blisters, and prurigo-like lesions with scarring, affecting the 
head and upper trunk in an elderly patient. Histologically, eosinophilia with erosion or 
subepidermal blistering is observed in the majority of the BPP cases. Nevertheless, 
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Figure 1. Polymorphous clinical features of Brunsting-Perry pemphigoid: 
erythematous inflamed, light infiltrated area with scarring and milia formation in the 

















































Table I. Demographics, clinical characteristics and histological parameters of the 
patients included 
 N=12 % Mean SD 
Gender Female 2 16.7%   
Male 10 83.3%   
Age at diagnosis (yrs)   73.1 11.2 
Age at symptoms onset (yrs)   70.9 12.4 
Diagnostic delay (yrs)   3.0 4.7 
Localization* 12    
Head/face/neck  12 100.0%   
Upper body  5 41.7%   
Oral  4 33.3%   
Other  1 8.3%   
Clinical features* 12    
Bullous lesions  8 66.7%   
Ulcerations  11  91.7%   
Erosions  8 66.7%   
Scales  3 25.0%   
Histological diagnosis* 12    
Spongiosis 1 8.3%   
Scarring/Fibrosis 5 41.7%   
Subepidermal blister 7 58.3%   
Eosinophils 8 66.7%   
Erosions 5 41.7%   
Other 3 25.0%   
DIF* 12    
Linear C3/IgG 11 91.7%   
Other linear autoantibodies 5 41.7%   
Unspecific DIF 1 8.3%   
ELISA 11    
BP180 3 27.3%   








BP180 + 230 1 9.1 %   
Negative 6 54.5%   
No data 1 -   
IIF 10    
Positive**  4 40.0%   
Negative  6 60.0%   
No data  2 -   
ELISA + IIF*  10    
Both negative  4 40.0%   
At least one positive  6 60.0%   
Both positive  2 20.0%   
No data  2 -   
DIF: direct immunofluorescence, ELISA: enzyme-linked immunosorbent assay, IgG: immunoglobuline 
G, IIF: indirect immunofluorescence, yrs: years, N: number, SD: standard deviation 
* More than one category may be present at the same time 
** All IIF positive cases (4) were evaluated in the roof of the bulla 
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